[go: up one dir, main page]

IL165398A - A method for identifying immunoreactive peptides - Google Patents

A method for identifying immunoreactive peptides

Info

Publication number
IL165398A
IL165398A IL165398A IL16539804A IL165398A IL 165398 A IL165398 A IL 165398A IL 165398 A IL165398 A IL 165398A IL 16539804 A IL16539804 A IL 16539804A IL 165398 A IL165398 A IL 165398A
Authority
IL
Israel
Prior art keywords
peptides
immunoreactive peptides
identifying
tumorous
identifying immunoreactive
Prior art date
Application number
IL165398A
Other languages
Hebrew (he)
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of IL165398A publication Critical patent/IL165398A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

The invention relates to a method for identifying immunoreactive peptides. According to said method, a sample consisting of tumorous and corresponding healthy tissue is first prepared, the tumour-specific expression profile is subsequently determined and antigenic peptides are isolated from the tumorous tissue and analysed. The respective data that has been obtained is then matched and peptides are identified on the basis of said matched data.
IL165398A 2002-05-29 2004-11-25 A method for identifying immunoreactive peptides IL165398A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10225139A DE10225139A1 (en) 2002-05-29 2002-05-29 Methods for the identification of immunoreactive peptides
PCT/EP2003/005038 WO2003100432A2 (en) 2002-05-29 2003-05-14 Method for identifying immunoreactive peptides

Publications (1)

Publication Number Publication Date
IL165398A true IL165398A (en) 2013-04-30

Family

ID=29557590

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16539803A IL165398A0 (en) 2002-05-29 2003-05-14 Method for identifying immunoreactive peptides
IL165398A IL165398A (en) 2002-05-29 2004-11-25 A method for identifying immunoreactive peptides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL16539803A IL165398A0 (en) 2002-05-29 2003-05-14 Method for identifying immunoreactive peptides

Country Status (13)

Country Link
EP (1) EP1508047B1 (en)
JP (1) JP2005535299A (en)
AT (1) ATE403874T1 (en)
AU (1) AU2003236645B2 (en)
CA (1) CA2486738C (en)
CY (1) CY1108358T1 (en)
DE (2) DE10225139A1 (en)
DK (1) DK1508047T3 (en)
ES (1) ES2311710T3 (en)
IL (2) IL165398A0 (en)
PT (1) PT1508047E (en)
SI (1) SI1508047T1 (en)
WO (1) WO2003100432A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2351995T3 (en) * 2004-06-17 2011-02-14 Mannkind Corporation PROFILES OF ANTIGENS ASSOCIATED WITH TUMORS IN THE DIAGNOSIS OF CANCER AND IMMUNOTHERAPY.
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
CA2651796A1 (en) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201019331D0 (en) * 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
WO2017194170A1 (en) 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR102379955B1 (en) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 Mating Enhanced T Cell Receptor
DE102016123893A1 (en) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T cell receptors with improved binding
CN110996970A (en) 2017-06-02 2020-04-10 亚利桑那州立大学董事会 Method of creating personalized cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
DE102018122546B3 (en) 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh High-throughput peptide MHC affinity screening method for TCR ligands
DE102019114735A1 (en) * 2019-06-02 2020-12-03 PMCR GmbH Class I and II HLA tumor antigen peptides for the treatment of breast cancer
DE102019121007A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigen binding proteins that specifically bind to MAGE-A
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
PE20240779A1 (en) 2021-07-27 2024-04-17 Immatics Biotechnologies Gmbh ANTIGEN-BINDING PROTEINS THAT BIND SPECIFICALLY TO CT45
WO2025021979A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
WO2025021968A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Antigen binding proteins against mageb2
LU103243B1 (en) 2024-02-09 2025-08-11 PMCR GmbH Click chemistry hla tumor antigen polypeptides and pharmaceutical composition comprising the same
WO2025168848A1 (en) 2024-02-09 2025-08-14 IMMUNEO Therapeutics GmbH Hla tumor antigen polypeptides with delivering aiding capping peptides and pharmaceutical composition comprising the same
WO2025233420A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Use of anti-cancer molecules
WO2025233431A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156317A (en) * 1996-11-12 2000-12-05 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
DE10225144A1 (en) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh Tumor-associated peptides binding to MHC molecules

Also Published As

Publication number Publication date
WO2003100432A2 (en) 2003-12-04
DE10225139A1 (en) 2004-02-26
CA2486738A1 (en) 2003-12-04
WO2003100432A3 (en) 2004-06-03
SI1508047T1 (en) 2008-12-31
IL165398A0 (en) 2006-01-15
ES2311710T3 (en) 2009-02-16
PT1508047E (en) 2008-10-02
EP1508047A2 (en) 2005-02-23
JP2005535299A (en) 2005-11-24
CA2486738C (en) 2011-07-12
DK1508047T3 (en) 2008-10-20
EP1508047B1 (en) 2008-08-06
CY1108358T1 (en) 2014-02-12
AU2003236645A1 (en) 2003-12-12
ATE403874T1 (en) 2008-08-15
DE50310283D1 (en) 2008-09-18
AU2003236645B2 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
IL165398A (en) A method for identifying immunoreactive peptides
CY1110295T1 (en) TRANS-9,10-DEHYDROPHOTHYLINE C AND D, ITS analogues and methods of preparation
DE60321256D1 (en) Speech recognition system, speech recognition method and program product
ATE478381T1 (en) DATA PROCESSING PROCEDURES
CY1108765T1 (en) ANTI-ErbB2 antibody treatment
EA199900162A1 (en) INHIBITORS OF CELLULAR ADHESION
BR0200282A (en) System and method for determining specific requirements from general requirements documents
JPWO2019222657A5 (en)
ATE517340T1 (en) SETS OF DIGITAL ANTIBODIES DIRECTED AGAINST SHORT EPITOPES AND METHODS USING THEM
EA200001129A2 (en) METHOD OF OBTAINING 4-CARBOXYAMINO-2-SUBSTITUTE-1,2,3,4-TETRAHYDROCHINOLINE
DE60239467D1 (en) HUMANIZED ANTIBODIES DERIVED FROM DD 3B6 / 22 SPECIFIC TO THE D-DIMER FRAGMENT OF FIBRIN
WO2003073818A3 (en) Proteomic analysis of tumors for development of consultative report of therapeutic options
PT1267915E (en) METHODS FOR TREATING DISEASES WITH PROTEIN C ACTIVATED
ES2502366T3 (en) Induction of tumor immunity by folate-binding protein variants
ES2285735T3 (en) MOLECULAR MODEL FOR VLA-4 INHIBITORS.
WO2003073351A3 (en) Screening process
AT500651B1 (en) ACTIVE IMMUNIZING ANTIBODY
DE60329663D1 (en) PROOF SPECIFIC NITRATED MARKER
ATE500273T1 (en) METHODS FOR ANALYZING ANTIBODY DISULFIDE ISOMERS
DE50210890D1 (en) AUTOMATIC IDENTIFICATION AND / OR VERIFICATION OF RICH TEXTURES SUCH AS FINGERPRINTS
AU2002365104A1 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
ATE437650T1 (en) TYROSINASE MUTANT AND METHOD FOR USE THEREOF
ITRM20020307A0 (en) EQUIPMENT FOR THE TREATMENT OF SKIN LESIONS, AND RELATED METHOD.
WO2001092313A3 (en) Methods for isolating and using fungal hemolysins
WO2003029482A3 (en) Diagnosing, treating, and preventing cancer using cables

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees
KB Patent renewed
KB Patent renewed